



Recipient Information

1. Recipient Name

CITY OF LAREDO
1110 Houston St
Laredo, TX 78040-8019
--

2. Congressional District of Recipient

28

3. Payment System Identifier (ID)

1746001573A1

4. Employer Identification Number (EIN)

746001573

5. Data Universal Numbering System (DUNS)

618150460

6. Recipient's Unique Entity Identifier (UEI)

HWX7C56NNUV1

7. Project Director or Principal Investigator

Ms. Erika Martinez
Assistant Director
emartinez8@ci.laredo.tx.us
956-795-4922

8. Authorized Official

Mr. Joe Neeb
jneeb@ci.laredo.tx.us
956-791-7398

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Kasheena Holland
Grants Management Specialist
dfb7@cdc.gov
4044980773

10. Program Official Contact Information

Ms. Anita Washington
Public Health Advisor
czo9@cdc.gov
770-488-4104

Federal Award Information

11. Award Number

5 NUR3DD000115-04-00

12. Unique Federal Award Identification Number (FAIN)

NUR3DD000115

13. Statutory Authority

42 USC 241 31 USC 6305 42 CFR 52

14. Federal Award Project Title

Enhancing Public Health Surveillance of Autism Spectrum Disorder through the Autism and Developmental Disabilities Monitoring (ADDM) Network

15. Assistance Listing Number

93.998

16. Assistance Listing Program Title

Autism and Other Developmental Disabilities, Surveillance, Research, and Prevention

17. Award Action Type

Non-Competing Continuation

18. Is the Award R&D?

No

Summary Federal Award Financial Information

19. Budget Period Start Date	01/01/2026	- End Date	12/31/2026
20. Total Amount of Federal Funds Obligated by this Action			\$450,000.00
20a. Direct Cost Amount			\$409,274.00
20b. Indirect Cost Amount			\$40,726.00
21. Authorized Carryover			\$0.00
22. Offset			\$0.00
23. Total Amount of Federal Funds Obligated this budget period			\$0.00
24. Total Approved Cost Sharing or Matching, where applicable			\$0.00
25. Total Federal and Non-Federal Approved this Budget Period			\$450,000.00
26. Period of Performance Start Date	04/01/2023	- End Date	12/31/2026
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance			\$2,250,000.00

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Mrs. Merlin Williams
Team Lead Grants Management Officer

30. Remarks



Recipient Information	
Recipient Name CITY OF LAREDO 1110 Houston St Laredo, TX 78040-8019 --	
Congressional District of Recipient 28	
Payment Account Number and Type 1746001573A1	
Employer Identification Number (EIN) Data 746001573	
Universal Numbering System (DUNS) 618150460	
Recipient's Unique Entity Identifier (UEI) HWX7C56NNUV1	
31. Assistance Type Cooperative Agreement	
32. Type of Award Other	

33. Approved Budget (Excludes Direct Assistance)	
I. Financial Assistance from the Federal Awarding Agency Only	
II. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$238,133.00
b. Fringe Benefits	\$111,968.00
c. Total Personnel Costs	\$350,101.00
d. Equipment	\$0.00
e. Supplies	\$11,435.00
f. Travel	\$0.00
g. Construction	\$0.00
h. Other	\$47,738.00
i. Contractual	\$0.00
j. TOTAL DIRECT COSTS	\$409,274.00
k. INDIRECT COSTS	\$40,726.00
l. TOTAL APPROVED BUDGET	\$450,000.00
m. Federal Share	\$450,000.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes						
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	ASSISTANCE LISTING	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
3-939ZRDY	23NUR3DD000115	DD	410Q	93.998	\$0.00	75-23-0958
4-939ZRDY	23NUR3DD000115	DD	410Q	93.998	\$0.00	75-24-0958
5-939ZRDY	23NUR3DD000115	DD	410Q	93.998	\$0.00	75-25-0958
6-939ZRDY	23NUR3DD000115	DD	410Q	93.998	\$450,000.00	75-26-0958



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NUR3DD000115-04-00

FAIN# NUR3DD000115

Federal Award Date: 01/09/2026

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

CITY OF LAREDO

5 NUR3DD000115-04-00

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federal-regulations-policies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-DD23-2301, entitled Enhancing Public Health Surveillance of Autism Spectrum Disorder through the Autism and Developmental Disabilities Monitoring (ADDM) Network, and application dated September 8, 2025, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NOA).

Total Approved Funding is included in Summary Federal Award Financial Information on page 1 of the NOA. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Approved Component/Project Funding: The NOFO provides for the funding of multiple components under this award. For this NOA, the approved funding level for each component is shown below:

NOFO Component	Amount
Component A	\$ 450,000

Financial Assistance Mechanism: Cooperative Agreement

Summary Statement/Technical Review: Within 5 days of this Notice of Award's (NOA) issue date, the Summary Statement/Technical Review will be accessible to the recipient in GrantSolutions Grant Messages. Contact the assigned Program Officer indicated in the NOA with any questions regarding this document or any follow up requirements and timelines set forth therein.

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities as detailed in the NOFO and included below.

- **Assist recipients with surveillance activities including the development of a standardized surveillance case definition and operationalization based on the collaborative use of the ADDM Network model by the ADDM Network.**

- ***Provide technical consultation regarding surveillance methods including data collection and abstraction, quality assurance, evaluation, analyses, and reporting.***
- ***Share with recipients the CDC ADDM Network data collection system used by the ADDM Network for tracking, abstraction, and data management of children with autism spectrum disorder and other developmental disabilities.***
- ***Conduct initial training and provide ongoing technical support in surveillance procedures for abstraction and data management personnel.***
- ***Provide tools and guidelines for extracting clean record-level de-identified data that does not contain the 18 HIPAA variables to be submitted by sites contributing to the ADDM Network pooled datasets.***
- ***Provide updated information on relevant CDC, US Department of Health and Human Services (HHS), and other policies and regulations that affect the programs.***
- ***Lead priority analyses and priority publications from each surveillance year (e.g., MMWR prevalence reports).***

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of carried over unobligated funds in Section 12 “Remarks” of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient’s authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

- Recipients may not use funds for research.

- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
- See [Additional Requirement \(AR\) 12](#) for detailed guidance on this prohibition and [additional guidance on lobbying for CDC recipients](#).
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.

Indirect Costs:

The recipient's indirect costs are approved and based on a de minimis rate of fifteen (15) percent of modified total direct costs (MTDC) as defined in 2 CFR 200.414(f), effective September 10, 2020.

REPORTING REQUIREMENTS

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132 "Performance Progress and Monitoring Report"**, **Expiration Date** The components of the PPMR are available for download at: <https://www.cdc.gov/grants/already-have-grant/Reporting.html> .

PAYMENT INFORMATION

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified beginning on the bottom of Page 2 of the Notice of Award must be known in order to draw down funds.

CLOSEOUT REQUIREMENTS

Standard closeout reporting requirements are identified in the General Terms and Conditions, which are published on the CDC website at <https://www.cdc.gov/grants/federal-regulations-policies/index.html>.